Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 24, Issue 19, Pages -Publisher
MDPI
DOI: 10.3390/ijms241914862
Keywords
targeted exon skipping; antisense oligonucleotide; ASO; splicing; RNA therapy; cancer; bioinformatics
Ask authors/readers for more resources
Precision medicine in oncology has made significant progress, but many cancer driver genes are still difficult to target with drugs. RNA-based methods, such as antisense oligonucleotides (ASOs), can induce targeted exon skipping (ES) and provide a promising alternative. This work presents a comprehensive computational procedure for developing ES-based cancer treatments, including target-exon selection, in silico prediction of ES products, and identification of optimal ASOs for experimental validation.
Precision medicine in oncology has made significant progress in recent years by approving drugs that target specific genetic mutations. However, many cancer driver genes remain challenging to pharmacologically target (undruggable). To tackle this issue, RNA-based methods like antisense oligonucleotides (ASOs) that induce targeted exon skipping (ES) could provide a promising alternative. In this work, a comprehensive computational procedure is presented, focused on the development of ES-based cancer treatments. The procedure aims to produce specific protein variants, including inactive oncogenes and partially restored tumor suppressors. This novel computational procedure encompasses target-exon selection, in silico prediction of ES products, and identification of the best candidate ASOs for further experimental validation. The method was effectively employed on extensively mutated cancer genes, prioritized according to their suitability for ES-based interventions. Notable genes, such as NRAS and VHL, exhibited potential for this therapeutic approach, as specific target exons were identified and optimal ASO sequences were devised to induce their skipping. To the best of our knowledge, this is the first computational procedure that encompasses all necessary steps for designing ASO sequences tailored for targeted ES, contributing with a versatile and innovative approach to addressing the challenges posed by undruggable cancer driver genes and beyond.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available